Designating ephedrine and pseudoephedrine products as schedule V controlled
substances; restricting the sale of methamphetamine precursor drugs and imposing
criminal penalties for violation, exceptions; requiring the reporting of
suspicious transactions to owners, supervisors or managers of business
establishments offering for sale methamphetamine precursor drugs; specifying
immunity from civil liabiltiy; specifying certain certification and publication
duties of the board of pharmacy
(ra)